AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS
AbbVie announced Qulipta hit the mark in its Phase III study by reducing mean monthly migraine days compared to placebo. Learn more about this migraine treatment here.
The Business Research Company (TBRC), a market research and intelligence firm, released a promising analysis of the global psoriatic arthritis treatment market.
AbbVie and Alvotech have settled a case, granting Alvotech a non-exclusive license to all Humira-related patents in the United States beginning on July 1, 2023.
China has become a leader in biotech in the last five years, especially in CAR-T therapies. Companies like Johnson & Johnson are on the prowl to acquire Chinese companies to form collaborations.
AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion.
Chicago-based AbbVie has been making major decisions with company-wide impacts. The therapeutic company appears to be making changes that will benefit its bottom line.
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week’s clinical trial news.
Biopharma companies are continuously working to test new treatments to the market. Here are three clinical updates announced this week, spanning three different continents.
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
JOBS
IN THE PRESS